Boston Scientific CMO Dawkins: We're working on renal denervation too

Fri, 10/19/2012 - 2:14pm
Mass Device

Boston Scientific CMO Dr. Keith Dawkins says the medical device company is working on a renal denervation system to treat hypertension.

Boston Scientific

Boston Scientific (NYSE:BSX) is running an internal program to develop a renal denervation device, Dr. Keith Dawkins told this week.

Heading into next week's Transcatheter Cardiovascular Therapies 2012 conference in Miami, the Natick, Mass.-based medical device company's global chief medical officer told us that BSX is planning to highlight several technologies at the show.

A single-electrode renal denervation system will go into its 1st human trials over "the next few months," Dawkins told us. Boston Scientific is also working on a double-electrode device, he added.

"We're looking at being able to reduce the time it takes to do an ablation," Dawkins said.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.